Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKRFCO)

Drug Name
CDX-301 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematopoietic stem cell transplantation QB63 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 2 [1]
Multiple myeloma 2A83 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMKRFCO

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fms-like tyrosine kinase 3 (FLT-3) TTGJCWZ FLT3_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hematopoietic stem cell transplantation
ICD Disease Classification QB63
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fms-like tyrosine kinase 3 (FLT-3) DTT FLT3 2.11E-01 -0.05 -0.16
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02129075) CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015 Jul;50(7):924-30.